Competitive Landscape Of General Surgery Devices

Introduction

The competitive landscape of general surgery devices is characterized by rapid advancements, technological innovations, and a growing demand for minimally invasive procedures. Key players in this market are constantly evolving their product portfolios to meet the increasing need for precision, safety, and efficiency in surgical interventions. Leading companies such as Johnson & Johnson, Medtronic, and Stryker dominate the space, leveraging their extensive research and development capabilities to maintain a competitive edge. Meanwhile, emerging players are focusing on niche markets and disruptive technologies, such as robotic surgery and AI-driven solutions, to capture market share. As healthcare systems prioritize cost-effectiveness and improved patient outcomes, the general surgery devices market is expected to witness sustained growth, with ongoing competition driving further innovation and expansion.

In 2023, Medtronic dominated the market with an overall USD 8.4 billion net sales within the general surgery devices portfolio, driven by its Surgical Innovations and Medical Surgical divisions. These segments emphasize advanced technologies in respiratory, gastrointestinal, and renal care, reinforcing Medtronic's leadership. BD (Becton, Dickinson, and Company) followed with around USD 1.5 billion in sales in the surgical segment, offering products like hernia repair, biosurgery, and infection prevention. Although smaller in revenue, BD's focus on specialized products adds considerable value to the surgical market.

Stryker generated approximately USD 5 billion in its MedSurg segment, which includes surgical equipment, safety technologies, and communication systems. Stryker’s diverse portfolio, covering both surgical and emergency medical equipment, positions it as a strong competitor, particularly in enhancing patient and caregiver safety.

These companies are key players in the competitive landscape, with Medtronic leading in scale, Stryker excelling in product diversity, and BD focusing on specialized solutions, all contributing to market growth.

Drivers of General Surgery Devices Market

1. Rising Prevalence of Chronic Diseases: The increasing occurrence of chronic conditions such as cancer, cardiovascular diseases, and obesity is boosting the demand for surgical interventions, driving growth in the general surgery devices market. According to the Australian Bureau of Statistics data published in December 2023, 49.9% had at least one chronic condition, and 81.4% had one long-term health condition. The most common chronic conditions were mental and behavioral issues (26.1%), back problems (15.7%), and arthritis (14.5%).

2. Advancements in Minimally Invasive Technologies: Advancements in minimally invasive technologies are transforming the general surgery devices market. For example, robotic-assisted systems like the da Vinci Surgical System enable surgeons to perform complex procedures with enhanced precision through small incisions. Innovations such as advanced laparoscopic tools and high-definition endoscopes improve visualization and control during surgery. These technologies reduce patient trauma, minimize recovery time, and lower the risk of complications. The integration of smart suturing devices and real-time imaging further enhances surgical outcomes. Overall, these advancements facilitate safer, more effective surgeries and contribute to the growing preference for minimally invasive approaches in general surgery.

3. Aging Population: As the global population ages, there is an increasing demand for surgeries, especially in cardiovascular and orthopedic fields, which drives the need for advanced surgical devices. For instance, WHO data from October 2022 indicates that the percentage of people over 60 is expected to nearly double, rising from 12% in 2015 to 22% by 2050. This demographic shift highlights the growing necessity for sophisticated surgical solutions to address age-related health issues.

Key Players Product Overview

Here is a table summarizing the general surgery device products from each key player, highlighting their features and differences:

Recent Developments

• In February 2024, Virtual Incision Corporation's MIRA Surgical System, the first miniaturized robotic-assisted surgery device, received FDA approval for adult colectomy procedures. The device, classified through the De Novo process, will expand into gynecology, general surgery, urology, and other fields. Trials for gynecology and a new version for general surgery are underway.

• In June 2024, St. Joseph Hospital in Maine has implemented robotic surgery to enhance precision in minimally invasive procedures. The new technology allows surgeons to perform complex surgeries with greater accuracy and reduced recovery times, marking a significant advancement in patient care and surgical capabilities at the hospital.

• In November 2023, Johnson & Johnson plans to submit its OTTAVA general surgery robot system to the FDA in 2024 for clinical trials. OTTAVA integrates into standard surgical tables, offering flexibility in the operating room with its four arms and Ethicon surgical instruments. The design aims to improve workflow, safety, and patient access, building on the company's MedTech portfolio.

• In January 2023, Amrita Hospital in Faridabad introduced the Da Vinci Surgical System, advancing its capabilities with robotic assisted, minimally invasive procedures. This technology is designed to improve surgical precision and shorten patients' recovery times. According to their statement, the hospital now provides state-of-the-art surgical options for gastro-surgical, uro-surgical, gyneco-oncologic, general, cardiothoracic, and head and neck cancer surgeries.

• In September 2022, Olympus Corporation launched the THUNDERBEAT Open Fine Jaw Type X surgical energy device for use in open surgeries. This device, equipped with a new thermal shield, is designed to improve safety during operations. Now available in Japan, it is part of the THUNDERBEAT series, which integrates ultrasonic and bipolar energy for efficient tissue handling and bleeding control.

SSI Innovations Marks a Milestone In Human Telesurgery:

Overview of Innovation: SSI Innovations has recently achieved a milestone in human telesurgery with the launch of the SSi Mantra 3 surgical robotic system. This system, used in a pioneering trial, allowed a surgeon and patient to be five kilometers apart while conducting a successful gallbladder removal via Airtel’s fiberoptic network. The SSi Mantra 3 represents a significant advancement in robotic-assisted surgery, combining precision and remote operability.

Impact on Healthcare: The SSi Mantra 3 is notable for its minimal incision requirements, leading to less pain, reduced blood loss, and faster recovery times. This innovative system is cost-effective, making advanced robotic surgery more accessible beyond major urban centers. The device has already been utilized in over 1,400 surgeries across various specialties, demonstrating its broad-spectrum applications and effectiveness.

Future Growth and Expansion: Looking ahead, SSI Innovations plans to expand its impact by pursuing regulatory approvals in the U.S. and Europe, aiming for FDA and CE Mark approvals by 2025. The company is also targeting underserved markets in Asia, Africa, Europe, and the Americas. The introduction of tele-proctoring and tele-mentoring capabilities further positions the SSi Mantra 3 as a transformative tool in global healthcare, promising to enhance surgical training and accessibility worldwide.

Recent Investments Highlight Growth in Surgical Technologies and Healthcare Startups

1. Surgical Instruments Expands with New Facility: UK-based Surgical Instruments Group Holdings (SIGH) is investing USD 2.31 billion to establish a medical device manufacturing facility in Hyderabad for its global expansion. In its first phase, this facility will produce general surgical instruments, precision tools for micro-surgeries, orthopedic power tools, and more. In phase two, SIGH plans to manufacture robotic medical devices. The investment decision was made during a meeting between SIGH's Managing Director and Telangana's Chief Minister at the World Economic Forum in Davos, marking a significant entry into the Indian market.

This expansion is set to enhance the company’s production capabilities and meet the growing demand for advanced surgical tools. The new facility will strengthen its position in the global market, reflecting a broader trend of increasing investment in medical technology infrastructure.

2. MyKare Health Secures Funding for Elective Surgeries: Elective surgeries startup MyKare Health has raised USD 2.01 million in its latest funding round. This capital infusion will support the company's growth and expansion efforts, enabling it to enhance its services and reach more patients. The investment underscores the rising interest in innovative healthcare solutions and startups that aim to streamline elective surgical procedures.

3. Virtual Incision Raises Additional USD 30M in Series C Funding: Virtual Incision has extended its Series C funding round, securing an additional USD 30 million. This new funding will aid in advancing the development of its miniaturized robotic-assisted surgery system, MIRA, and expanding its market presence. The investment highlights the increasing confidence in telesurgery technologies and their potential to revolutionize remote surgical capabilities.

These investments reflect a broader trend towards enhancing surgical technology and expanding innovative healthcare solutions, signaling continued growth and evolution in the medical industry.